Vesugen (Lys-Glu-Asp) is the short synthetic peptide assigned to vascular tissue in the Khavinson scheme. Ventfort is the corresponding extract preparation.
Reported endpoints are largely laboratory markers and cell-culture behaviour. Cardiovascular event data is not something we have seen in English. [source needed]
Papers on this tissue
Educational summary only. Not medical advice, and not a product endorsement. Read the source paper before you repeat anything here.